Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 936 trials

Head and Neck Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This trial looks at its use alone and with other standard treatments to see how well it works.

Recurrent Head and Neck CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

B-cell Acute Lymphoblastic Leukemia: CD19-CAR T Cell Therapy

We are testing a new type of CAR T cell therapy for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The study aims to evaluate the safety and appropriate dosage of this treatment.

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Breast Cancer: Study of OKI-219 Treatment

We are investigating a new treatment called OKI-219 for patients with breast cancer. This study looks at how it works alone and with other therapies to improve outcomes.

Advanced Breast CancerSolid Tumor>2 yearsSafety phase (I)Oncology

Gastrointestinal Tolerability: Tegomil vs. Dimethyl Fumarate

We are comparing how well healthy volunteers tolerate two oral medications for gastrointestinal side effects. This study aims to understand which option may be easier on the stomach.

Multiple Sclerosis3-6 monthsSafety phase (I)Neurology

Hepatitis B: SAMBA Study on Antibodies

We are investigating the safety and effects of new antibodies for people with hepatitis B. This study aims to learn more about how these treatments may help manage the disease.

Chronic Hepatitis BSafety phase (I)HepatologyInfectious Diseases

Advanced Solid Tumors: Sigvotatug Vedotin

We are studying a new treatment for patients with advanced solid tumors to see how well it works compared to current options. This research aims to improve outcomes for those affected by these cancers.

Cervical CancerHead and Neck CancerGastric Cancer>2 yearsSafety phase (I)Oncology

Lung Cancer: Chemoimmunotherapy with MEK Inhibitor

We are testing a new treatment combining chemotherapy and a MEK inhibitor for patients with metastatic non-squamous non-small cell lung adenocarcinoma. The goal is to see if this approach is safe and effective for those with low PD-L1 levels.

Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Oncology

Milvexian: Comparing Tablet Formulations for Kids and Adults

We are studying how different tablet forms of milvexian are absorbed in healthy adults and how food affects this process. We also want to know if participants find these formulations acceptable.

Atherothrombotic and Thromboembolic DisordersSafety phase (I)CardiologyInternal Medicine

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Heart Failure: COR-1167 Study

We are testing a new medication, COR-1167, to see how safe it is and how the body processes it in people with chronic heart failure and healthy volunteers. This study aims to gather important information about its effects.

Chronic Heart Failure>2 yearsSafety phase (I)CardiologyInternal Medicine

Crimean Congo Hemorrhagic Fever: N-pVAX1 Vaccine Study

We are evaluating a new DNA vaccine to see if it is safe and can help the body fight against Crimean Congo Hemorrhagic Fever. This study is for healthy volunteers who want to contribute to vaccine research.

Congo-Crimean Hemorrhagic FeverSafety phase (I)Infectious Diseases

Advanced Head and Neck Cancer: TG4050 Gene Therapy

We are testing a personalized gene therapy for patients with advanced head and neck cancer. The goal is to see if it can improve treatment outcomes compared to standard options.

Head and Neck Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)OncologyOtolaryngology

Multiple Myeloma: AZD0305 Treatment Study

We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Chronic Lymphocytic Leukemia: Intermittent Ibrutinib Study

We are investigating whether taking ibrutinib intermittently can improve outcomes for people with chronic lymphocytic leukemia. This study aims to find out if this approach is effective compared to continuous treatment.

Chronic Lymphocytic LeukemiaSafety phase (I)HematologyOncology

Advanced Solid Tumors: PM54 Treatment

We are testing a new treatment called PM54 for patients with advanced solid tumors. The goal is to evaluate its safety and how well it works compared to existing options.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

JJP-1212: New Immune Response Treatment

We are assessing whether JJP-1212 is safe and can effectively stimulate an immune response in humans. This study aims to understand its tolerability and potential benefits.

Linear IgA Bullous Dermatosis>2 yearsSafety phase (I)DermatologyInfectious Diseases

Thyroid Eye Disease: Lu AG22515 Treatment

We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.

Thyroid Eye Disease1-2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Gastrointestinal Cancers: MK-2870 Treatment Study

We are testing the safety and effectiveness of MK-2870, alone or with other cancer treatments, for people with gastrointestinal cancers. This study aims to see how well it works in reducing tumors and improving patient outcomes.

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Biliary Tract Cancer6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: Neoadjuvant Triple Treatment Study

We are exploring a new combination of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer. The goal is to see if this treatment improves survival and surgical outcomes.

Pancreatic CancerBorderline Resectable Pancreatic Cancer (BRPC)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology